Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Rating of "Hold" from Analysts
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) has been given an average rating of "Hold" by the six brokerages that are currently covering the company, MarketBeat Ratings...
MarketBeat·3d ago
More News
Silence Therapeutics (NASDAQ:SLN) Shares Down 5.1% - Here's What Happened
Silence Therapeutics (NASDAQ:SLN) Trading Down 5.1% - Time to Sell...
MarketBeat·5d ago
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of "Hold" from Brokerages
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) has earned a consensus recommendation of "Hold" from the six brokerages that are presently covering the stock, Marketbeat...
MarketBeat·28d ago
Silence Therapeutics (NASDAQ:SLN) Trading Down 0.7% - Should You Sell?
Silence Therapeutics (NASDAQ:SLN) Shares Down 0.7% - Should You Sell...
MarketBeat·1mo ago
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of "Hold" from Analysts
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) has been given an average rating of "Hold" by the six research firms that are presently covering the firm, MarketBeat Ratings...
MarketBeat·2mo ago
Silence Therapeutics Announces Leadership Changes
Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has...
Business Wire·2mo ago
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat...
Business Wire·3mo ago
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced it has completed patient enrollment in the SANRECO...
Business Wire·4mo ago
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus
Zacks·8mo ago
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet